GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TEYI PHARMACEUTICAL GROUP CO LTD (SZSE:002728) » Definitions » Debt-to-Revenue

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Debt-to-Revenue : 0.45 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is TEYI PHARMACEUTICAL GROUP CO Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

TEYI PHARMACEUTICAL GROUP CO's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥296.0 Mil. TEYI PHARMACEUTICAL GROUP CO's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0.0 Mil. TEYI PHARMACEUTICAL GROUP CO's annualized Revenue for the quarter that ended in Mar. 2024 was ¥658.4 Mil. TEYI PHARMACEUTICAL GROUP CO's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.45.


TEYI PHARMACEUTICAL GROUP CO Debt-to-Revenue Historical Data

The historical data trend for TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TEYI PHARMACEUTICAL GROUP CO Debt-to-Revenue Chart

TEYI PHARMACEUTICAL GROUP CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 1.65 0.87 0.96 0.29

TEYI PHARMACEUTICAL GROUP CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.63 0.71 0.24 0.45

Competitive Comparison of TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue falls into.



TEYI PHARMACEUTICAL GROUP CO Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(306 + 0) / 1067.212
=0.29

TEYI PHARMACEUTICAL GROUP CO's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(296 + 0) / 658.448
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


TEYI PHARMACEUTICAL GROUP CO Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of TEYI PHARMACEUTICAL GROUP CO's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Business Description

Traded in Other Exchanges
N/A
Address
Industrial Park pit, Guangdong Province, North, Taishan, CHN
TEYI PHARMACEUTICAL GROUP CO LTD is a pharmaceutical company. It engages in the research and development, production, and sale of proprietary Chinese medicines, and chemical drugs and raw materials in China. The main pharmaceutical preparation products cover a cough and phlegm, kidney, anti-infection, cardiovascular and digestive system. The main preparation products include Zhikebao Tablet, Jinqi Shenqi Tablet, Pharyngitis Tablet, and Erythromycin Enteric-coated Tablets.
Executives
Zhang Yong Zhao Executives
Chen Xi Liang Directors, Directors, and Executives
Xu Shao Hua Securities Affairs Representative
Xu Wei Gao Director
Xu Song Qing Directors, executives
Liu Guang Tao Executives
Du Yong Chun Supervisors
Huang Yan Ling Executives
Chen Guang Ting Supervisors

TEYI PHARMACEUTICAL GROUP CO (SZSE:002728) Headlines

No Headlines